Plegridy

E24878

Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.

Jump to: Statements Referenced by

Statements (51)

Predicate Object
instanceOf disease-modifying therapy
medication
pegylated interferon beta-1a
activeIngredient peginterferon beta-1a
belongsToClass immunomodulatory agents
interferon beta-1a
hasAdministrationFrequency every 14 days
hasApprovalAuthority European Medicines Agency
Food and Drug Administration
surface form: U.S. Food and Drug Administration
hasATCCode L03AB13
hasBlackBoxWarning risk of depression and suicide
risk of hepatotoxicity
hasCommonSideEffect chills
flu-like symptoms
headache
injection site reactions
myalgia
pyrexia
hasContraindication history of suicidal ideation
severe depression
severe hepatic impairment
hasDeveloper Biogen
hasDosageForm pre-filled pen
pre-filled syringe
solution for injection
hasEffect reduces MRI lesion activity
reduces relapse rate in multiple sclerosis
slows disability progression
hasLegalStatusEU prescription only
hasLegalStatusUS prescription only
hasManufacturer Biogen
hasMechanismOfAction immunomodulation
reduction of inflammatory responses in multiple sclerosis
hasPregnancyCategoryUS C
hasRouteOfAdministration subcutaneous
subcutaneous injection
hasSeriousSideEffect depression
hepatotoxicity
pulmonary arterial hypertension
suicidal ideation
thrombotic microangiopathy
hasTradeName Plegridy self-link
isAdministeredTo adults
isPegylated true
isUsedFor long-term treatment of multiple sclerosis
treats active secondary progressive multiple sclerosis
clinically isolated syndrome
relapsing forms of multiple sclerosis
relapsing-remitting multiple sclerosis
wasApprovedInEU 2014
wasApprovedInUS 2014

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

Biogen hasProduct Plegridy
Plegridy hasTradeName Plegridy self-link